Mumbai Port Trust allots 156 dormitory blocks to Tata Memorial Centre for treatment of kids suffering from cancer

The Mumbai Port Trust , in a gesture has allotted 156 dormitory blocks to the Tata Memorial Centre for the children suffering from cancer. These children will be treated free of charge here, as per media reports.
The project undertaken by the Mumbai Port Trust was part of its Corporate Social Responsiblity (CSR) which was initiated in 2015. The move will surely help those children suffering from cancer, who come to Mumbai along with their parents from across the country, some media reports have said.
Earlier this month, in a major relief for cancer patients across the country, drug pricing regulator NPPA had slashed price of cancer medicines by close to 86 percent since March last year. In a tweet, he National Pharmaceutical Pricing Authority (NPPA) had also said that there has been “a significant price reduction in cancer drug prices since March 2016”.
The price of drugs like Iressa of AstraZeneca Pharma India was brought down from Rs 29,259 to Rs 3,977and Dr Reddy’s laboratories’ Grafeel – of which price was lashed by 41 percent, it said. As per the NPPA, the drop in the price range of 86 per cent to 13 per cent, NPPA said.
Source: http://www.financialexpress.com/india-news/mumbai-port-trust-allots-156-dormitory-blocks-to-tata-memorial-centre-for-treatment-of-kids-suffering-from-cancer/607686/

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that BMTP
Read more